The present disclosure describes a method of delivering a therapeutic agent providing a microneedle array including a plurality of microneedles, the plurality of microneedles including a conductive coating disposed thereon, wherein the conductive coating includes the therapeutic agent and a conducting polymer; implanting the microneedle array in a dura mater of a subject in need thereof, wherein the microneedle array pierces the dura mater; and applying an electrical stimulus to the microneedle array to provide a controlled release of the therapeutic agent from the conductive coating, across the dura mater, to the central nervous system of the subject.

Drug delivery devices and methods of controlled drug delivery to a patient are provided. The drug delivery device may include one or two microchip elements, each of which has a body portion with one or more drug release apertures in fluid communication with at least one containment reservoir. The drug release apertures are closed off by one or more reservoir caps which can be electrically activated to open the drug release apertures. The drug delivery device also includes (i) a drug formulation disposed in the at least one containment reservoir, and (ii) at least one drug-permeable membrane. In some cases, an outer housing is spaced a distance from an exterior wall of the body portion of the microchip element, the outer housing includes the at least one drug-permeable membrane, and a depot space is defined between the drug-permeable membrane and the exterior wall of the body portion of the microchip element.

The presently disclosed subject matter describes the use of fluorinated elastomer-based materials, in particular perfluoropolyether (PFPE)-based materials, in high-resolution soft or imprint lithographic applications, such as micro- and nanoscale replica molding, and the first nano-contact molding of organic materials to generate high fidelity features using an elastomeric mold. Accordingly, the presently disclosed subject matter describes a method for producing free-standing, isolated nanostructures of any shape using soft or imprint lithography technique.

A pharmaceutical product including a housing that defines a cavity, wherein the cavity stores a pharmaceutical material, and wherein the housing comprises a material configured to dissolve based on contact with a fluid, an ingestible device to encode information in a current signature, wherein the ingestible device is positioned within the housing, and a protective material that encompasses the ingestible device. The ingestible device may be attached to a flexible component, wherein the flexible component is configured to releasably secure the ingestible device within the housing.

A solid dosage product having a tailored dissolution profile comprises a carrier block defining a plurality of compartments where each respective compartment is configured to receive one or more active pharmaceutical ingredient and the carrier block being digestible within an animal such that each respective active pharmaceutical ingredient is controllably released; and one or more coating layers applied to the carrier block. A method for manufacturing a solid dosage product having a tailored dissolution comprises manufacturing a digestible carrier block where the carrier block defines a plurality of compartments with each respective compartment configured to receive an active pharmaceutical ingredient; filling a respective compartment with a respective active pharmaceutical ingredient; and coating the carrier block with one or more coating layers.

Various embodiments of the present disclosure include a consumable capsule containing an active ingredient in at least one compartment movably sealed by a stimuli responsive actuator, and an activation device configured to communicate with the consumable capsule. The activation device is configured to emit a wireless signal to activate the stimuli responsive actuator of the consumable capsule, and the consumable capsule is configured to release the active ingredient into an external environment based on the activation of the stimuli responsive actuator.

This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a PDE4 inhibitor.

Various embodiments of an oral delivery capsule device for delivering an active agent to a part of a gastrointestinal (GI) tract of a subject are described. The capsule device may include a capsule body configured to travel along the GI tract. The capsule device may include a reservoir configured to contain an active agent for delivery to the GI tract of the subject. The oral delivery capsule device may include an actuation feature configured to provide a delivery force thereby causing the dispensing of the active agent. The oral delivery capsule device may include an actuation control feature configured to prevent actuation of the actuation feature under a first condition and allow actuation under a second condition. Related systems and methods are also described.

An implantable drug delivery device and method for delivering a drug to a living body. The device includes a housing having at least one opening, a reservoir within the housing adapted to contain the drug, a temporary seal closing the at least one opening of the housing, and a heating element in thermal contact with the temporary seal. The heating element is adapted to generate heat in response to a magnetic field to melt the temporary seal and release the drug within the reservoir through the at least one opening of the housing.

The invention features a pharmaceutical suspension containing drug particles, a drug delivery device anchored in the mouth for continuously administering the pharmaceutical suspension, and methods of their use.